Status:
COMPLETED
AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Squamous Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\<60, 60-69, 70-...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer
Exclusion
- Contraindications to Avastin treatment according to the Summary of Product Characteristics
Key Trial Info
Start Date :
March 14 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2017
Estimated Enrollment :
1107 Patients enrolled
Trial Details
Trial ID
NCT01827852
Start Date
March 14 2013
End Date
May 31 2017
Last Update
July 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universität Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie
Leipzig, Germany, 04103